Skip to main content
Karo Pharma AB logo

Karo Pharma AB — Investor Relations & Filings

Ticker · KARO ISIN · SE0007464888 LEI · 213800G54Z51LOPGTA79 ST Manufacturing
Open in API
Filings indexed 653 across all filing types
Latest filing 2020-04-01 Report Publication Anno…
Country SE Sweden
Listing ST KARO

About Karo Pharma AB

https://www.karohealthcare.com/

Karo Pharma AB, operating as Karo Healthcare, is a healthcare company that develops, markets, and sells a broad portfolio of everyday healthcare products. The company's offerings are designed to prevent illness and treat common health problems, empowering consumers to manage their daily well-being. The portfolio consists of various branded medicines and consumer healthcare products distributed through pharmacies and directly to healthcare providers. With products available in over 90 countries, the company focuses on becoming a leading force in its sector by employing a consumer-centric approach, strategic innovation, and omnichannel excellence.

Recent filings

Filing Released Lang Actions
Report Publication Announcement 2020
Report Publication Announcement Classification · 98% confidence The document is very short (822 characters) and its primary purpose is to announce that Karo Pharma has published its annual report ('årsredovisning') for 2019 on its website on April 1, 2020. It does not contain the actual content of the annual report. According to Rule #2 (The 'MENU VS MEAL' Rule), a short announcement stating that a report has been published points towards a Report Publication Announcement (RPA). The title 'Karo Pharma publicerar årsredovisning för 2019' (Karo Pharma publishes annual report for 2019) confirms this is an announcement, not the full 10-K/AR document itself.
2020-04-01 Swedish
Report Publication Announcement 2020
Report Publication Announcement Classification · 98% confidence The document text explicitly states: "Karo Pharma publishes the 2019 annual report" and then immediately follows up with information about where and when it was published ("Today, on 1April 2020, Karo Pharma is publishing its annual report for 2019 on the company's website"). The document itself is very short (800 characters) and serves primarily to announce the availability of the full 2019 Annual Report, rather than containing the full content of the Annual Report (10-K). According to Rule #2 (The 'MENU VS MEAL' Rule), a short announcement stating a report has been published points towards a Report Publication Announcement (RPA).
2020-04-01 English
Karo Pharma senarelägger årsstämman till 25 maj, 2020
AGM Information Classification · 95% confidence The document is a short announcement from Karo Pharma stating that the Annual General Meeting (AGM) has been postponed from April 29, 2020, to May 25, 2020, due to COVID-19 concerns. This is a direct announcement regarding the scheduling and logistics of the AGM. While it relates to the AGM, it is not the presentation material itself (AGM-R) nor a proxy solicitation (PSI). It is a specific announcement concerning the meeting's timing, which fits best under the general category of regulatory/corporate announcements, but given the specific focus on the AGM date change, it is most closely related to the AGM process. However, since there isn't a specific code for 'AGM postponement notice,' and it is a corporate action announcement, I must check the definitions. It is not a DVA (Voting Results), DEF 14A (Remuneration), or PSI (Proxy Solicitation). Since it is a specific corporate event update, and the document is very short (1014 chars) and announces a change related to a shareholder meeting, it is a type of corporate disclosure. Given the options, and the fact that it is an announcement about the AGM logistics, it is not a standard filing type like 10-K or IR. It is a specific corporate event update. If we consider the closest fit among the provided codes, it is an announcement related to the AGM. Since there is no specific 'AGM Announcement' code, and it is not a voting result (DVA), I will classify it as a general regulatory announcement (RNS) or look for a better fit. The document is about the AGM schedule. If we look at the definitions, AGM-R is for 'Presentations and materials shared during the Annual General Meeting (AGM)'. This is a notice *about* the AGM, not the materials. Given the lack of a perfect fit for a simple schedule change notice, RNS (Regulatory Filings - fallback) is often used for such specific, non-standard corporate news. However, since the core subject is the AGM, and it is a formal corporate communication, I will re-evaluate. Since it is a direct announcement about the AGM date, and not a voting result or proxy material, it is a specific corporate event notice. I will classify it as RNS as it is a general regulatory announcement that doesn't fit the more specific codes like DVA or AGM-R (which implies materials). The document length is very short, suggesting it's not a comprehensive report.
2020-03-27 Swedish
Karo Pharma postpones the Annual General Meeting to 25 May, 2020
AGM Information Classification · 95% confidence The document explicitly states that the 'Annual General Meeting' (AGM) has been postponed to a new date (May 25, 2020). This is an announcement directly related to the scheduling and logistics of the AGM, rather than the presentation materials themselves (AGM-R) or a general regulatory filing (RNS). Since there is a specific category for AGM-related information, AGM-R is the most appropriate fit, as it covers presentations and materials shared during the AGM, and scheduling announcements are intrinsically linked to the meeting itself.
2020-03-27 English
Karo Pharma completes the acquisition of product portfolio from LEO Pharma
M&A Activity Classification · 98% confidence The document announces the completion of an acquisition of a product portfolio from LEO Pharma by Karo Pharma for 90 MEUR. This action directly relates to corporate restructuring, asset transfer, and changes in the company's business scope, which falls under the category of Mergers & Acquisitions (M&A) activity. The filing code corresponding to M&A activity is TAR (Takeover/Acquisition/Restructuring). The document is a formal announcement of a completed transaction, not a general regulatory filing or a report publication announcement.
2020-03-02 English
Karo Pharma slutför förvärvet av produktportfölj från Leo Pharma
M&A Activity Classification · 98% confidence The document announces the completion of an acquisition ('förvärvet av produktportfölj från Leo Pharma') for 90 MEUR. This is a significant corporate action related to business structure and assets, which falls under the scope of M&A activity or a major corporate event. The filing explicitly mentions the EU Market Abuse Regulation ('EU:s marknadsmissbruksförordning'), suggesting it is a mandatory disclosure. Since the core content is about a merger/acquisition/takeover proposal or completion, the most appropriate category is 'M&A Activity' (TAR). It is not an earnings release, a capital change, or a general regulatory filing, but a specific transaction announcement.
2020-03-02 Swedish

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.